博雅生物 reported revenue of ¥0.64B for the period ended 2026-06-30, -36.1% year on year. Net income was ¥0.05B, a 7.9% net margin on a 44.2% gross margin. The largest revenue line is 血液制品业务 at 84% of the total. Free cash flow for the period was ¥-0.10B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.64B | -36.1% |
| Gross profit | ¥0.28B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.05B | -77.4% |
| Gross margin | 44.2% | Net margin 7.9% |
| Revenue Q/Q | +0.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 血液制品业务 | ¥0.54B | 84.0% |
| 生化类用药业务 | ¥0.09B | 13.7% |
| 经销业务 | ¥0.01B | 2.3% |
| 其他(补充) | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.36B | 55.8% |
| R&D | ¥0.01B | 1.9% |
| SG&A | ¥0.25B | 39.1% |
| Tax & other | ¥-0.05B | -7.1% |
| Item | Amount |
|---|---|
| Total assets | ¥8.28B |
| Total liabilities | ¥0.84B |
| Shareholders' equity | ¥7.44B |
| Equity / assets | 89.9% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.10B |
| Free cash flow | ¥-0.10B |
| Cash conversion (OCF / net income) | -268% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
*ST三六五 ・ 利亚德 ・ 三诺生物 ・ 富春股份 ・ 海峡创新 ・ ST长方 ・ 同有科技 ・ 聚飞光电 ・ 云意电气 ・ 裕兴股份 ・ 远方信息 ・ 慈星股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies